Skip to main content
. 2021 Nov 18;40(1):63–71. doi: 10.1200/JCO.21.01194

FIG 3.

FIG 3.

Kaplan-Meier curves for PFS for (A) the entire cohort, and according to (B) relapsed or refractory disease, (C) number of previous lines of therapy, (D) prior BTKi exposure, (E) CXCR4 mutational status, and (F) IPSSWM. BTKi, Bruton tyrosine kinase inhibitor; IPSSWM, International Prognostic Scoring System for Waldenström Macroglobulinemia; MUT, mutated; PFS, progression-free survival; WT, wild-type.